<DOC>
	<DOCNO>NCT01063543</DOCNO>
	<brief_summary>Fondaparinux synthetic antithrombotic agent specific anti-factor Xa activity . A population pharmacokinetic model fondaparinux , base data obtain patient included phase II/III trial , describe . However , validity model everyday practice need confirm . This study multicenter , prospective cohort study consecutive orthopedic patient treat 2.5 mg fondaparinux . Anti-Xa activity record 809 patient . Population parameters inter-individual variability estimate use NONMEM VI software . A two-compartment model first-order absorption best describe fondaparinux pharmacokinetics . Covariates partly explain inter-individual variability body weight , age creatinine clearance estimate simplified Modification Diet Renal Disease formula . A body weight le 50 kg moderate renal failure increase drug exposure . These result suggest fondaparinux pharmacokinetics need confirm patient population fully assess phase II/III study</brief_summary>
	<brief_title>Pharmacokinetics Fondaparinux Patients With Major Orthopedic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>patient need leg major orthopedic surgery age &gt; 18 year patient need prophylactic dos fondaparinux contraindication fondaparinux renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>fondaparinux</keyword>
	<keyword>orthopedic surgery</keyword>
	<keyword>patient major orthopedic surgery</keyword>
</DOC>